Safety Shot, Inc. (NASDAQ: SHOT) shares were flat to begin Monday and the week, The Jupiter, Fla.-based company purports to be the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences.
The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer’s Blood Alcohol Content, successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.
The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot’s proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world’s first formula to aid in the rapid reduction of alcohol within the body.
SHOT shares dipped a penny, or 1.2%, first thing Monday to 71 cents.
Related Stories
